Alterações morfológicas foliares em abacaxizeiros cv. IAC "Gomo-de-mel" micropropagados e aclimatizados em diferentes condições de luminosidade Morphological alterations in leave of micropropagated pineapple plants cv. IAC "Gomo-de-mel" acclimatizated in different conditions of luminosity

Plantas micropropagadas geralmente apresentam dificuldades de adaptação ao meio ex vitro, sendo muitas vezes submetidas a processos de rustificação para minimizar os impactos decorrentes da mudança de ambiente. Uma vez que a folha e seus anexos destacam-se como importantes indicativos das estratégias adaptativas das plantas a ambientes adversos, este trabalho teve por objetivo comparar a anatomia foliar de plantas de abacaxi cv. IAC "Gomo-de-mel" cultivadas in vitro com microplantas aclimatizadas em diferentes condições de luminosidade, sob telado com 50% de sombreamento e em pleno sol para verificar a necessidade do processo de rustificação para este cultivar. Avaliações por meio de microscopia de luz e eletrônica de varredura da epiderme foliar, demonstraram aumento na densidade de escamas em ambas as superfícies das folhas, em microplantas dos ambientes ex vitro, principalmente em relação às que foram expostas diretamente ao sol. Observou-se ainda, aumento no espessamento da cutícula, na sinuosidade das células epidérmicas, e na distribuição e quantidade de fibras no mesofilo evidenciando a interferência das condições de luminosidade nas características morfológicas das microplantas. Essas alterações não prejudicaram o desenvolvimento das microplantas, indicando que não são necessárias etapas de rustificação para a aclimatização deste cultivar.<br>Microprapagated plants usually show difficulties to adapt to ex vitro conditions, and many times are submitted to the rustication process to aim the reduction of all the impacts resulting from the environmental changes. Once the leaf and its annexes are important indicators of adaptability strategies of the plants to adverse environmental conditions, the objective of this work was to compare the leaf anatomy of pineapple cv. IAC "Gomo-de-mel" in vitro cultivated plants with microplants acclimatized in different conditions of luminosity, under mesh, with 50 % of shading and directly exposed to sunlight, to verify the needed of rustication process on this cultivar. Evaluations of the leaf epidermis using light and electronic scanning microscopy showed an increase on scale density in both leaves surfaces of the ex vitro microplants, mainly related to the ones directly exposed to sunlight. Subsequent observations showed an increase on cuticle thickness, on wavy contours of epidermal cells, and on the distribution and quantity of mesophyll fibers, evidencing the light conditions interference in morphological characteristics of these microplants. These alterations had not harmed microplant development, showing that are not need of rustication stages on the acclimatization process of this cultivar

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)